Evotec AG O.N. (EVTG)

36.410
+0.620(+1.73%)
  • Volume:
    194,339
  • Bid/Ask:
    36.390/36.420
  • Day's Range:
    35.740 - 36.910
  • Type:Equity
  • Market:Germany
  • ISIN:DE0005664809
  • WKN:566480

EVTG Overview

Prev. Close
35.79
Day's Range
35.74-36.91
Revenue
514.62M
Open
35.74
52 wk Range
21.31-43
EPS
0.25
Volume
194,339
Market Cap
5.88B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
326,541
P/E Ratio
143.55
Beta
0.7
1-Year Change
58.29%
Shares Outstanding
164,366,392
Next Earnings Date
Aug 11, 2021
What is your sentiment on Evotec AG O.N.?
or
Vote to see community's results!

Evotec AG O.N. News

Evotec AG O.N. Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellBuyStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy

Evotec AG O.N. Company Profile

Evotec AG O.N. Company Profile

Employees
3735
Market
Germany

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company’s EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company’s portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women’s health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.

Read More
  • To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
    0
    • lol railing Melvin Capital left and right
      0
      • Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
        0
    • The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.